Financials data is unavailable for this security.
View more
Year on year Hainan Huluwa Pharmaceutical Group Co Ltd grew revenues 25.75% from 1.52bn to 1.91bn while net income improved 24.29% from 85.68m to 106.50m.
| Gross margin | 51.16% |
|---|---|
| Net profit margin | 7.09% |
| Operating margin | 7.82% |
| Return on assets | 4.61% |
|---|---|
| Return on equity | 11.14% |
| Return on investment | 7.36% |
More ▼
Cash flow in CNYView more
In 2023, Hainan Huluwa Pharmaceutical Group Co Ltd increased its cash reserves by 12.31%, or 57.10m. Cash Flow from Financing totalled 553.06m or 29.03% of revenues. In addition the company generated 28.25m in cash from operations while cash used for investing totalled 524.21m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.87 |
|---|---|
| Tangible book value per share | 2.13 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.08 |
|---|---|
| Quick ratio | 0.8243 |
| Total debt/total equity | 1.20 |
|---|---|
| Total debt/total capital | 0.5374 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 24.29%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.29% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 40.37% |
| EPS growth(5 years) | -2.78 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 38.54 |
More ▼
